The average one-year price target for CEL-SCI (NYSEAM:CVM) has been revised to $25.50 / share. This is a decrease of 91.67% from the prior estimate of $306.00 dated July 15, 2025. The price target is ...
Stocktwits on MSN
Why did CVM shares rally over 7% today?
Following the transaction, Geert R. owns 120,815 shares of the company. ・Cel-Sci is most known for its experimental cancer treatment called Multikine. ・The company is currently preparing to conduct a ...
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results